www.marketreportsonchina.com
As a category of biological products, a Blood Product is a kind of biological active preparation manufactured based on health human blood plasma with biological techniques or plasma separation and purification technologies. According to patients of different diseases, different contents of plasma protein are separated and manufactured into specific blood products. Blood products can be categorized into human serum albumin, human immunoglobulin and coagulation factors that have a widest variety of products.
www.marketreportsonchina.com
The concentration rate of global blood product industry is rather high. The four enterprises of developed countries, CSL Behring, Baxter, Grifols and Octapharma, occupy over 80% of global market shares. Currently, the global blood industry maintains relatively stable, with emerging markets serving as major driving forces. According to China will become one of the major global blood product markets as its economy develops. Chinese government imposes strict regulations on production, sales and import of blood products. In addition, the government implements a lot release system of biological products (including blood products and vaccines), compulsorily inspecting and verifying every batch of such products when leaving factory or being imported. www.marketreportsonchina.com
According to market research by about 30 blood product manufacturers have been authenticated by the Chinese government by the end of 2017. But indeed, only 20 of them operate under normal production. Since 2012, mergers and acquisitions have emerged in China's blood product industry. Examples include Jiangxi Boya Bio-Pharmaceutical Co., Ltd. purchasing partial stake of Zhejiang Haikang Biological Products Co., Ltd., Beijing Tiantan Biological Products Co., Ltd. acquiring Chengdu Rosen Pharmaceutical Co., Ltd. and Humanwell Healthcare Group Co., Ltd. acquiring Wuhan Rui De Biological Products Co., Ltd.
www.marketreportsonchina.com
In 2001, the Chinese government announced that new blood product manufacturers would be no longer authenticated for the safety of blood and blood products. If overseas blood product manufacturers desire to enter Chinese market, they can either export their products directly to China or acquire existing blood product manufacturers in China. For example, in August 2017, CSL Behring spent USD 352 million on purchasing 80% stake of Wuhan Zhongyuan Rui De Biological Products Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. On the third of August, 2017, CSL officially announced that it had completed the deal with Humanwell and had taken over business operations of Rui De. CSL Behring temporarily launched only albumin on Chinese market. www.marketreportsonchina.com
I Basic Concept of Blood Products 1.1 Definition of Blood Products 1.2 Classification of Blood Products 1.2.1 Albumin 1.2.2 Immune Globulin 1.2.3 Coagulation Factors 1.2.4 Other Categories II Overview of Global Blood Product Industry, 20132017 2.1 Industry Overview 2.1.1 Development Process 2.1.2 Market Competition 2.1.3 Supply Status 2.1.4 Demand Status www.marketreportsonchina.com
Contact Us Phone No: +91 22 27810773 Email: info@marketreportsonchina.com Website: http://www.marketreportsonchina.com Twitter: https://twitter.com/ReportsonChina Facebook: https://www.facebook.com/chinamarketreport LinkedIn: https://www.linkedin.com/company/3694978